Aranzazu Fernandez-Martinez1,2, Ian E Krop3, David W Hillman4, Mei-Yin Polley4, Joel S Parker1,2, Lucas Huebner4, Katherine A Hoadley1,2, Jonathan Shepherd1,2, Sara Tolaney3, N Lynn Henry5, Chau Dang6, Lyndsay Harris7, Donald Berry8, Olwen Hahn9, Clifford Hudis6, Eric Winer3, Ann Partridge3, Charles M Perou1,2, Lisa A Carey1,10. 1. Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC. 2. Department of Genetics, University of North Carolina, Chapel Hill, NC. 3. Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA. 4. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN. 5. University of Michigan Rogel Cancer Center, Ann Arbor, MI. 6. Memorial Sloan Kettering Cancer Center, New York, NY. 7. National Cancer Institute, Cancer Diagnostics Program, Bethesda, MD. 8. Division of Biostatistics, MD Anderson Cancer Center, Houston, TX. 9. Alliance Protocol Operations Office, University of Chicago, Chicago, IL. 10. Division of Hematology-Oncology, University of North Carolina, Chapel Hill, NC.
Abstract
PURPOSE: CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) -targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures that predict pCR and survival. PATIENTS AND METHODS: Three hundred five women with untreated stage II and III HER2-positive breast cancer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL), trastuzumab (TH), or lapatinib (TL). The primary end point was pCR, and secondary end points included RFS, OS, and gene expression analyses. mRNA sequencing was performed on 264 pretreatment samples. RESULTS:One hundred eighteen patients were randomly allocated to THL, 120 to TH, and 67 to TL. At more than 7 years of follow-up, THL had significantly better RFS and OS than did TH (RFS hazard ratio, 0.32; 95% CI, 0.14 to 0.71; P = .005; OS hazard ratio, 0.34; 95% CI, 0.12 to 0.94; P = .037), with no difference between TH and TL. Of 688 previously described gene expression signatures, significant associations were found in 215 with pCR, 45 with RFS, and only 22 with both pCR and RFS (3.2%). Specifically, eight immune signatures were significantly correlated with a higher pCR rate and better RFS. Among patients with residual disease, the immunoglobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature, which was associated with a higher pCR rate, showed a significantly shorter RFS. CONCLUSION: In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.
RCT Entities:
PURPOSE: CALGB 40601 assessed whether dual versus single humanepidermal growth factor receptor 2 (HER2) -targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures that predict pCR and survival. PATIENTS AND METHODS: Three hundred five women with untreated stage II and III HER2-positive breast cancer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL), trastuzumab (TH), or lapatinib (TL). The primary end point was pCR, and secondary end points included RFS, OS, and gene expression analyses. mRNA sequencing was performed on 264 pretreatment samples. RESULTS: One hundred eighteen patients were randomly allocated to THL, 120 to TH, and 67 to TL. At more than 7 years of follow-up, THL had significantly better RFS and OS than did TH (RFS hazard ratio, 0.32; 95% CI, 0.14 to 0.71; P = .005; OS hazard ratio, 0.34; 95% CI, 0.12 to 0.94; P = .037), with no difference between TH and TL. Of 688 previously described gene expression signatures, significant associations were found in 215 with pCR, 45 with RFS, and only 22 with both pCR and RFS (3.2%). Specifically, eight immune signatures were significantly correlated with a higher pCR rate and better RFS. Among patients with residual disease, the immunoglobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature, which was associated with a higher pCR rate, showed a significantly shorter RFS. CONCLUSION: In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.
Authors: Aleix Prat; Giampaolo Bianchini; Marlene Thomas; Anton Belousov; Maggie C U Cheang; Astrid Koehler; Patricia Gómez; Vladimir Semiglazov; Wolfgang Eiermann; Sergei Tjulandin; Mikhail Byakhow; Begoña Bermejo; Milvia Zambetti; Federico Vazquez; Luca Gianni; José Baselga Journal: Clin Cancer Res Date: 2014-01-15 Impact factor: 12.531
Authors: Maki Tanioka; Cheng Fan; Joel S Parker; Katherine A Hoadley; Zhiyuan Hu; Yan Li; Terry M Hyslop; Brandelyn N Pitcher; Matthew G Soloway; Patricia A Spears; Lynn N Henry; Sara Tolaney; Chau T Dang; Ian E Krop; Lyndsay N Harris; Donald A Berry; Elaine R Mardis; Eric P Winer; Clifford A Hudis; Lisa A Carey; Charles M Perou Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Lisa A Carey; Donald A Berry; Constance T Cirrincione; William T Barry; Brandelyn N Pitcher; Lyndsay N Harris; David W Ollila; Ian E Krop; Norah Lynn Henry; Douglas J Weckstein; Carey K Anders; Baljit Singh; Katherine A Hoadley; Michael Iglesia; Maggie Chon U Cheang; Charles M Perou; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Gunter von Minckwitz; Chiun-Sheng Huang; Max S Mano; Sibylle Loibl; Eleftherios P Mamounas; Michael Untch; Norman Wolmark; Priya Rastogi; Andreas Schneeweiss; Andres Redondo; Hans H Fischer; William Jacot; Alison K Conlin; Claudia Arce-Salinas; Irene L Wapnir; Christian Jackisch; Michael P DiGiovanna; Peter A Fasching; John P Crown; Pia Wülfing; Zhimin Shao; Elena Rota Caremoli; Haiyan Wu; Lisa H Lam; David Tesarowski; Melanie Smitt; Hannah Douthwaite; Stina M Singel; Charles E Geyer Journal: N Engl J Med Date: 2018-12-05 Impact factor: 176.079
Authors: Debora Fumagalli; David Venet; Michail Ignatiadis; Hatem A Azim; Marion Maetens; Françoise Rothé; Roberto Salgado; Ian Bradbury; Lajos Pusztai; Nadia Harbeck; Henry Gomez; Tsai-Wang Chang; Maria Antonia Coccia-Portugal; Serena Di Cosimo; Evandro de Azambuja; Lorena de la Peña; Paolo Nuciforo; Jan C Brase; Jens Huober; José Baselga; Martine Piccart; Sherene Loi; Christos Sotiriou Journal: JAMA Oncol Date: 2017-02-01 Impact factor: 31.777
Authors: Katherine L McNamara; Jennifer L Caswell-Jin; Rohan Joshi; Zhicheng Ma; Eran Kotler; Gregory R Bean; Michelle Kriner; Zoey Zhou; Margaret Hoang; Joseph Beechem; Jason Zoeller; Michael F Press; Dennis J Slamon; Sara A Hurvitz; Christina Curtis Journal: Nat Cancer Date: 2021-04-08
Authors: Pat W Whitworth; Peter D Beitsch; Mary K Murray; Paul D Richards; Angela Mislowsky; Carrie L Dul; James V Pellicane; Paul L Baron; Rakhshanda Layeequr Rahman; Laura A Lee; Beth B Dupree; Pond R Kelemen; Andrew Y Ashikari; Raye J Budway; Cristina Lopez-Penalver; William Dooley; Shiyu Wang; Patricia Dauer; Andrea R Menicucci; Erin B Yoder; Christine Finn; Lisa E Blumencranz; William Audeh Journal: JCO Precis Oncol Date: 2022-09
Authors: Youli Xia; Xiaping He; Lorna Renshaw; Carlos Martinez-Perez; Charlene Kay; Mark Gray; James Meehan; Joel S Parker; Charles M Perou; Lisa A Carey; J Michael Dixon; Arran Turnbull Journal: Clin Cancer Res Date: 2022-08-15 Impact factor: 13.801
Authors: Ciara C O'Sullivan; Karla V Ballman; Linda McCall; Anuhya Kommalapati; Tyler Zemla; Anna Weiss; Melissa Mitchell; Victoria Blinder; Nadine M Tung; William J Irvin; Myounghee Lee; Matthew P Goetz; William Fraser Symmans; Virginia F Borges; Ian Krop; Lisa A Carey; Ann H Partridge Journal: Future Oncol Date: 2021-10-12 Impact factor: 3.674
Authors: Tomás Pascual; Aranzazu Fernandez-Martinez; Maki Tanioka; M Vittoria Dieci; Sonia Pernas; Joaquin Gavila; Valentina Guarnieri; Javier Cortes; Patricia Villagrasa; Núria Chic; Maria Vidal; Barbara Adamo; Montserrat Muñoz; Gaia Griguolo; Antonio Llombart; Pierfranco Conte; Mafalda Oliveira; Benedetta Conte; Laia Paré; Patricia Galvan; Lisa A Carey; Charles M Perou; Aleix Prat Journal: Clin Cancer Res Date: 2021-02-25 Impact factor: 12.531
Authors: Sung Gwe Ahn; Seon-Kyu Kim; Jonathan H Shepherd; Yoon Jin Cha; Soong June Bae; Chungyeul Kim; Joon Jeong; Charles M Perou Journal: Breast Cancer Res Treat Date: 2021-03-26 Impact factor: 4.872